BGB A317 - Beigene

Drug Profile

BGB A317 - Beigene

Alternative Names: BGB-A317

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fc receptor modulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Hodgkin's disease; Oesophageal cancer; Urogenital cancer
  • Phase I B cell lymphoma; Solid tumours

Most Recent Events

  • 28 Sep 2017 Adverse event and efficacy data from a phase I/II trial in Solid tumour released by BeiGene
  • 28 Sep 2017 BeiGene plans phase III registration-supporting trials for Lung cancer, Gastric cancer, Liver cancer and Oesophageal cancer in China in the fourth quarter of 2017 or first quarter of 2018
  • 27 Sep 2017 Peter MacCallum Cancer Centre plans the MYPHISMO phase I/II trial for Solid tumours including Colorectal cancer and Adenocarcinoma (Late-stage disease, Combination therapy) in Australia (NCT03287427)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top